Lantern Pharma Inc. (LTRN)
NASDAQ: LTRN · IEX Real-Time Price · USD
4.530
+0.120 (2.72%)
Jul 22, 2024, 9:45 AM EDT - Market open
Lantern Pharma Employees
Lantern Pharma had 21 employees as of December 31, 2023. The number of employees decreased by 2 or -8.70% compared to the previous year.
Employees
21
Change (1Y)
-2
Growth (1Y)
-8.70%
Revenue / Employee
n/a
Profits / Employee
-$834,980
Market Cap
48.25M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Bionano Genomics | 344 |
Apyx Medical | 252 |
Vicarious Surgical | 131 |
NextCure | 82 |
DURECT | 58 |
Modular Medical | 40 |
Elicio Therapeutics | 32 |
Protara Therapeutics | 27 |
LTRN News
- 12 days ago - Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184 - Business Wire
- 5 weeks ago - Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284 - Business Wire
- 2 months ago - Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights - Business Wire
- 2 months ago - Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism - Business Wire
- 2 months ago - Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET - Business Wire
- 3 months ago - Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development - Business Wire
- 3 months ago - Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan - Business Wire
- 4 months ago - Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights - Business Wire